General Updates

September 29, 2026 To, To, BSE Limited, National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (East), Mumbai – 400001 Mumbai – 400051 Scrip code: 544889 Symbol: SYMBIOTEC Sub.: Symbiotec Pharmalab Receives Establishment Inspection Report (EIR) from U.S. FDA for its Pithampur (SEZ) Madhya Pradesh, India facility with VAI classification Dear Sir/Ma’am, Symbiotec Pharmalab Limited (“Symbiotec”), a research and development-driven, science-based pharmaceutical and biotechnology company, today announced that it has received the Establishment Inspection Report (“EIR”) from the U.S. Food and Drug Administration (U.S. FDA) for its manufacturing facility in Pithampur (“SEZ”), Madhya Pradesh India with a Voluntary Action Indicated (“VAI”) status. The inspection was conducted at the Company’s manufacturing facility at Pithampur, from August 10, 2026 to August 14, 2026. This is for your Information and Records. Thanking you, For Symbiotec Pharmalab Limited Salil Jain Company Secretary & Compliance Officer Registered Office & Works: Symbiotec Pharmalab Limited (Formerly known as Symbiotec Pharmalab Pvt. Ltd.) 385/2, Pigdamber, Rau, Mhow, Indore - 453331, Madhya Pradesh, India Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222, Email ID : symbiotec@symbiotec.com, Website : www.symbiotec.com CIN: U24232MP2002PLC015293